Two Of Aurobindo’s Europe Biosimilar Filings Stuck
Could MHRA Approve Bevacizumab Biosimilar Minus Phase III Trial?
Even as two biosimilar filings in Europe are stuck due to a lack of inspection staff and a biosimilar could be approved in the UK without a Phase III trial, Aurobindo has licensed novel drug Ryzneuta from Yifan Pharma. Meanwhile, a $650m-$700m revenue forecast for the specialty business has been pushed back as both overall revenues and profits declined during Q2.
